In our study, the lower median cTn I (as a subclinical myocardial injury biomarker) serum concentration in patients with T2DM, than those without T2DM (p = 0.013), could be a long-lasting effect of metformin, which has CVD benefits beyond its antihyperglycemic effects [18]. This evidence concerns the gene TNNI3 and type 2 diabetes mellitus.